Zeid Kayali | Hepatology | N Las Vegas, NV

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Enrollment Status: Completed

Publish Date: January 24, 2025

Intervention Type: Drug

Study Drug: Tirzepatide

Study Phase: Phase 2

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis

Enrollment Status: Terminated

Publish Date: October 01, 2024

Intervention Type: Drug

Study Drug: Obeticholic Acid

Study Phase: Phase 3

A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks

Enrollment Status: Completed

Publish Date: September 19, 2024

Intervention Type: Drug, Other

Study Drug: Cx601

Study Phase: Phase 3

A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Enrollment Status: Completed

Publish Date: June 21, 2024

Intervention Type: Drug

Study Drug: Ontamalimab

Study Phase: Phase 3

A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC

Enrollment Status: Completed

Publish Date: April 24, 2024

Intervention Type: Drug

Study Drug: HTD1801 (BUDCA)

Study Phase: Phase 2

A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness

Enrollment Status: Completed

Publish Date: April 11, 2024

Intervention Type: Drug

Study Drugs: Bamlanivimab, Etesevimab

Study Phase: Phase 2/Phase 3

Pharmacokinetics of Imlunestrant in Participants With Hepatic Impairment

Enrollment Status: Completed

Publish Date: March 29, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy

Enrollment Status: Terminated

Publish Date: January 09, 2024

Intervention Type: Drug

Study Phase: Phase 4

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Outpatients With Mild to Moderate COVID-19 Illness

Enrollment Status: Completed

Publish Date: January 02, 2024

Intervention Type: Drug

Study Drug: Proxalutamide (GT0918)

Study Phase: Phase 3

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

Enrollment Status: Active_not_recruiting

Publish Date: November 09, 2023

Intervention Type: Drug

Study Drug: Belapectin

Study Phase: Phase 2/Phase 3

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Enrollment Status: Completed

Publish Date: October 23, 2023

Intervention Type: Drug

Study Drug: Obeticholic acid

Study Phase: Phase 3

The Effect of Vitamin E and Docosahexaenoic Acid Ethyl Ester on Non-Alcoholic Fatty Liver Disease (NAFLD) - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

Enrollment Status: Completed

Publish Date: May 25, 2023

Intervention Type: Other, Dietary supplement, Combination product

Study Phase: Phase 2

A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis

Enrollment Status: Terminated

Publish Date: March 09, 2023

Intervention Type: Drug

Study Drug: Obeticholic Acid

Study Phase: Phase 4

A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment

Enrollment Status: Terminated

Publish Date: September 06, 2022

Intervention Type: Drug

Study Drug: Obeticholic Acid

Study Phase: Phase 4

A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment

Enrollment Status: Completed

Publish Date: July 18, 2022

Intervention Type: Drug

Study Phase: Phase 1

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)

Enrollment Status: Completed

Publish Date: July 01, 2022

Intervention Type: Drug

Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody

Study Phase: Phase 2

A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis

Enrollment Status: Terminated

Publish Date: April 27, 2022

Intervention Type: Drug

Study Drug: GSK2831781

Study Phase: Phase 2

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)

Enrollment Status: Terminated

Publish Date: March 31, 2022

Intervention Type: Drug, Other

Study Drug: Ontamalimab

Study Phase: Phase 3

A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

Enrollment Status: Completed

Publish Date: March 28, 2022

Intervention Type: Drug

Study Phase: Phase 1

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)

Enrollment Status: Completed

Publish Date: January 14, 2022

Intervention Type: Other, Drug

Study Phase: Phase 3

A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Enrollment Status: Completed

Publish Date: September 16, 2021

Intervention Type: Drug

Study Phase: Phase 2

The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study

Enrollment Status: Completed

Publish Date: August 30, 2021

Intervention Type: Combination product

Study Phase: Not Applicable

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)

Enrollment Status: Terminated

Publish Date: June 14, 2021

Intervention Type: Other, Drug

Study Phase: Phase 3

A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)

Enrollment Status: Completed

Publish Date: May 18, 2021

Intervention Type: Drug

Study Phase: Phase 2

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)

Enrollment Status: Terminated

Publish Date: April 29, 2021

Intervention Type: Other, Biological

Study Phase: Phase 3

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)

Enrollment Status: Completed

Publish Date: September 16, 2020

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis

Enrollment Status: Completed

Publish Date: June 17, 2020

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)

Enrollment Status: Terminated

Publish Date: November 25, 2019

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis

Enrollment Status: Completed

Publish Date: June 20, 2019

Intervention Type: Drug

Study Phase: Phase 1

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis

Enrollment Status: Unknown

Publish Date: March 19, 2019

Intervention Type: Drug

Study Drug: Emricasan

Study Phase: Phase 2

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)

Enrollment Status: Completed

Publish Date: January 07, 2019

Intervention Type: Drug

Study Phase: Phase 2

Dr. Zeid Kayali

Overview

Insurance

Locations

Additional Areas of Focus

Clinical Research

33 Clinical Trials

20 Total Publications

Areas of Expertise